[HTML][HTML] Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study
Annals of Oncology, 2016•Elsevier
Background Over the past decade, numerous reports describe the generation and
increasing utility of non-small-cell lung cancer (NSCLC) patient-derived xenografts (PDX)
from tissue biopsies. While PDX have proven useful for genetic profiling and preclinical drug
testing, the requirement of a tissue biopsy limits the available patient population, particularly
those with advanced oligometastatic disease. Conversely,'liquid biopsies' such as
circulating tumour cells (CTCs) are minimally invasive and easier to obtain. Here, we …
increasing utility of non-small-cell lung cancer (NSCLC) patient-derived xenografts (PDX)
from tissue biopsies. While PDX have proven useful for genetic profiling and preclinical drug
testing, the requirement of a tissue biopsy limits the available patient population, particularly
those with advanced oligometastatic disease. Conversely,'liquid biopsies' such as
circulating tumour cells (CTCs) are minimally invasive and easier to obtain. Here, we …
Background
Over the past decade, numerous reports describe the generation and increasing utility of non-small-cell lung cancer (NSCLC) patient-derived xenografts (PDX) from tissue biopsies. While PDX have proven useful for genetic profiling and preclinical drug testing, the requirement of a tissue biopsy limits the available patient population, particularly those with advanced oligometastatic disease. Conversely, ‘liquid biopsies’ such as circulating tumour cells (CTCs) are minimally invasive and easier to obtain. Here, we present a clinical case study of a NSCLC patient with advanced metastatic disease, a never smoker whose primary tumour was EGFR and ALK wild-type. We demonstrate for the first time, tumorigenicity of their CTCs to generate a patient CTC-derived eXplant (CDX).
Patients and methods
CTCs were enriched at diagnosis and again 2 months later during disease progression from 10 ml blood from a 48-year-old NSCLC patient and implanted into immunocompromised mice. Resultant tumours were morphologically, immunohistochemically, and genetically compared with the donor patient's diagnostic specimen. Mice were treated with cisplatin and pemetrexed to assess preclinical efficacy of the chemotherapy regimen given to the donor patient.
Results
The NSCLC CDX expressed lung lineage markers TTF1 and CK7 and was unresponsive to cisplatin and pemetrexed. Examination of blood samples matched to that used for CDX generation revealed absence of CTCs using the CellSearch EpCAM-dependent platform, whereas size-based CTC enrichment revealed abundant heterogeneous CTCs of which ∼80% were mesenchymal marker vimentin positive. Molecular analysis of the CDX, mesenchymal and epithelial CTCs revealed a common somatic mutation confirming tumour origin and showed CDX RNA and protein profiles consistent with the predominantly mesenchymal phenotype.
Conclusions
This study shows that the absence of NSCLC CTCs detected by CellSearch (EpCAM+) does not preclude CDX generation, highlighting epithelial to mesenchymal transition and the functional importance of mesenchymal CTCs in dissemination of this disease.
Elsevier